Ernexa Therapeutics Inc.
ERNA
$0.29
$0.001.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.03% | 60.47% | 61.73% | -42.42% | 78.35% |
| Total Depreciation and Amortization | -1.43% | 27.27% | -20.29% | 1.47% | -84.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 153.13% |
| Total Other Non-Cash Items | 188.16% | -135.92% | -81.89% | 1,164.50% | -97.89% |
| Change in Net Operating Assets | -117.92% | 155.14% | -323.89% | 115.84% | 56.49% |
| Cash from Operations | 9.75% | 49.76% | -22.62% | 41.75% | 43.60% |
| Capital Expenditure | 31.82% | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 31.82% | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -100.00% | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.47% | 123,125.00% | -99.65% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -99.47% | 118.68% | 123.17% | -74.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.28% | -152.90% | 1,168.25% | 107.46% | -4.88% |